Drug Profile
Fulvestrant intraductal - Atossa Therapeutics
Alternative Names: Fulvestrant - Atossa TherapeuticsLatest Information Update: 16 Jan 2022
Price :
$50
*
At a glance
- Originator Atossa Genetics
- Developer Atossa Therapeutics
- Class Antineoplastics; Estradiol congeners; Estrenes; Fluorinated hydrocarbons; Small molecules; Sulfoxides
- Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 14 Oct 2021 Discontinued - Phase-II for Breast cancer (Neoadjuvant therapy) in USA (Parenteral) (Atossa Therapeutics pipeline, October 2021)
- 18 Aug 2020 Atossa terminated the '007' phase II trial in Breast cancer (Neoadjuvant therapy) in USA, due to business decision (NCT02540330)
- 02 Mar 2016 Phase-II clinical trials in Breast cancer (Neoadjuvant therapy) in USA (Parenteral)